Long term follow-up of the neo-adjuvant pilot trial evaluating activity of letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and/or progesterone receptor positive primary breast cancer

被引：0
|
作者：
Forero, A.
Delos Santos, J.
Bowen, K.
Jones, C.
Varley, K. E.
Nabell, L.
Carpenter, J. T.
Falkson, C. I.
Krontiras, H.
Caterinicchia, V.
O'Malley, J.
Li, Y.
LoBuglio, A. F.
Myers, R.
Saleh, M. N.
机构：
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-P1-15-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-15-02
引用
收藏
页数：2
相关论文
共 16 条
  • [1] Long Term Follow-Up of a Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer
    Forero, A.
    Saleh, M.
    Galleshaw, J.
    Jones, C.
    Nabell, L.
    Carpenter, J.
    Falkson, C.
    Krontiras, H.
    Urist, M.
    Bland, K.
    De Los Santos, J.
    Meredith, R.
    Caterinicchia, V.
    Bernreuter, W.
    O'Malley, J.
    Yufeng, L.
    LoBuglio, A.
    CANCER RESEARCH, 2010, 70
  • [2] A Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer
    Forero, A.
    Saleh, M.
    Galleshaw, J.
    Jones, C.
    Shah, J.
    Percent, I
    Nabell, L.
    Carpenter, J.
    Falkson, C.
    Krontiras, H.
    Urist, M.
    Bland, K.
    De Los Santos, J.
    Meredith, R.
    Caterinicchia, V
    Bernreuter, W.
    O'Malley, J.
    Li, Y.
    LoBuglio, A.
    CANCER RESEARCH, 2009, 69 (24) : 567S - 567S
  • [3] Pilot Trial of Preoperative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Postmenopausal Women With Newly Diagnosed Estrogen Receptor-or Progesterone Receptor-Positive Breast Cancer
    Forero-Torres, Andres
    Saleh, Mansoor N.
    Galleshaw, Janice A.
    Jones, Cheryl F.
    Shah, Jatin J.
    Percent, Ivor J.
    Nabell, Lisle M.
    Carpenter, John T.
    Falkson, Carla I.
    Krontiras, Helen
    Urist, Marshall M.
    Bland, Kirby I.
    De Los Santos, Jennifer F.
    Meredith, Ruby F.
    Caterinicchia, Valerie
    Bernreuter, Wanda K.
    O'Malley, Janis P.
    Li, Yufeng
    LoBuglio, Albert F.
    CLINICAL BREAST CANCER, 2010, 10 (04) : 275 - 280
  • [4] A study of pre-operative letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed operable breast cancer: A preliminary safety report
    Percent, I. J.
    Forero, A.
    Galleshaw, J.
    Nabel, L.
    Carpenter, J.
    Falkson, C.
    Jones, C.
    Krontriras, H.
    Saleh, M.
    Santos, J. De Los
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (01) : 469 - 469
  • [5] A study of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed operable breast cancer: A preliminary safety report
    Forero-Torres, A.
    Percent, I.
    Galleshaw, J.
    Nabell, L.
    Carpenter, J.
    Falkson, C.
    Jones, C.
    Krontriras, H.
    De Los Santos, J.
    Saleh, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole versus letrozole (LET) in combination with bevacizumab (BEV) in post-menopausal women with newly diagnosed stage II/III breast cancer
    Forero-Torres, Andres
    Rugo, Hope S.
    Vaklavas, Christos
    Lin, Nancy U.
    Carey, Lisa A.
    Liu, Minetta C.
    Nanda, Rita
    Puhalla, Shannon
    Storniolo, Anna Maria
    Krontiras, Helen
    Saleh, Mansoor N.
    Li, Yufeng
    LoBuglio, Albert F.
    De Los Santos, Jennifer F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Evaluating the Efficacy of Current Clinical Practice of Adjuvant Chemotherapy in Post-Menopausal Women with One to Three Positive Auxiliary Nodes and Estrogen and/or Progesterone Positive Early Stage Breast Cancer
    Hannouf, M. B.
    Brackstone, M.
    Zaric, G.
    CANCER RESEARCH, 2010, 70
  • [8] Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy
    Hojo, Takashi
    Kinoshita, Takayuki
    Imoto, Shigeru
    Shimizu, Chikako
    Isaka, Hirotsugu
    Ito, Hiroki
    Imi, Kentaro
    Wada, Noriaki
    Ando, Masashi
    Fujiwara, Yasuhiro
    BREAST, 2013, 22 (03): : 263 - 267
  • [9] Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
    Ruhstaller, Thomas
    Giobbie-Hurder, Anita
    Colleoni, Marco
    Jensen, Maj-Britt
    Ejlertsen, Bent
    de Azambuja, Evandro
    Neven, Patrick
    Lang, Istvan
    Jakobsen, Erik Hugger
    Gladieff, Laurence
    Bonnefoi, Herve
    Harvey, Vernon J.
    Spazzapan, Simon
    Tondini, Carlo
    Del Mastro, Lucia
    Veyret, Corinne
    Simoncini, Edda
    Gianni, Lorenzo
    Rochlitz, Christoph
    Kralidis, Elena
    Zaman, Khalil
    Jassem, Jacek
    Piccart-Gebhart, Martine
    Di Leo, Angelo
    Gelber, Richard D.
    Coates, Alan S.
    Goldhirsch, Aron
    Thuerlimann, Beat
    Regan, Meredith M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (02) : 105 - +
  • [10] Neo-Adjuvant Exemestane in Post Menopausal Estrogen and/or Progesterone Receptor Positive Breast Cancer: A Randomized Phase II Trial To Investigate Optimal Duration (4 Month Versus 6 Month) of Preoperative Endocrine Therapy (PTEX46 Trial)
    Hojo, T.
    Kinoshita, T.
    Wada, N.
    Imoto, S.
    Tamura, N.
    Nagao, T.
    Ando, M.
    Katsumata, N.
    Fujiwara, Y.
    CANCER RESEARCH, 2010, 70
12